Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM21 CAR-T in R/R Multiple Myeloma
NCT05478343Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM21 in multiple myeloma (MM), sponsored by Immunochina Pharmaceuticals. Primary endpoints: Incidence of adverse events at 28 days and Persistence of CAR-T cells at 24 weeks. Status: unknown.
02
Drugs
IM21
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05478343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478343.